Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy.

Objective: This study aimed to explore the effectiveness of brivaracetam (BRV) according to baseline seizure frequency and past treatment history in subjects with focal epilepsy who were included in the Brivaracetam Add-On First Italian Network Study (BRIVAFIRST).

Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adults prescribed adjunctive BRV. Study outcomes included sustained seizure response (SSR), sustained seizure freedom (SSF), and the rates of treatment discontinuation and adverse events (AEs).

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study.

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).

Background: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are generally under-represented in randomized placebo-controlled trials. Real-world studies can therefore be a useful complement to characterize the drug's profile.

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A.

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures.

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified.

Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection.

Objectives: To provide new insights into neurological manifestations of COVID-19. We describe a patient with mild COVID-19 associated with diplopia from right sixth cranial nerve palsy and early diffuse leukoencephalopathy, successfully treated with intravenous methylprednisolone.

Methods: The patient was evaluated for diplopia that occurred 1 day after the onset of fever, myalgia, and headache.

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.

Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Background: The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in the mid-1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack.

Evading the Vainshtein Mechanism with Anomalous Gravitational Wave Speed: Constraints on Modified Gravity from Binary Pulsars.

By using observations of the Hulse-Taylor pulsar, we constrain the gravitational wave (GW) speed to the level of 10(-2). We apply this result to scalar-tensor theories that generalize Galileon 4 and 5 models, which display anomalous propagation speed and coupling to matter for GWs. We argue that this effect survives conventional screening due to the persistence of a scalar field gradient inside virialized overdensities, which effectively "pierces" the Vainshtein screening.

New class of consistent scalar-tensor theories.

We introduce a new class of scalar-tensor theories of gravity that extend Horndeski, or "generalized Galileon," models. Despite possessing equations of motion of higher order in derivatives, we show that the true propagating degrees of freedom obey well-behaved second-order equations and are thus free from Ostrogradski instabilities, in contrast to standard lore. Remarkably, the covariant versions of the original Galileon Lagrangians-obtained by direct replacement of derivatives with covariant derivatives-belong to this class of theories.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Importance: The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS).

Objective: To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS.

Design, Setting, And Participants: The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab.

Implications of relativity on nonrelativistic Goldstone theorems: gapped excitations at finite charge density.

We adapt the Goldstone theorem to study spontaneous symmetry breaking in relativistic theories at finite charge density. It is customary to treat systems at finite density via nonrelativistic Hamiltonians. Here, we highlight the importance of the underlying relativistic dynamics.

Measuring deviations from a cosmological constant: a field-space parametrization.

Most parametrizations of the dark energy equation of state do not reflect realistic underlying physical models. Here we develop a relatively simple description of dark energy based on the dynamics of a scalar field which is exact in the limit that the equation of state approaches a cosmological constant, assuming some degree of smoothness of the potential. By introducing just two parameters defined in the configuration space of the field, we are able to reproduce a wide class of quintessence models.

Model for gravitational interaction between dark matter and baryons.

We propose a phenomenological model where the gravitational interaction between dark matter and baryons is suppressed on small, subgalactic scales. We describe the gravitational force by adding a Yukawa contribution to the standard Newtonian potential and show that this interaction scheme is effectively suggested by the available observations of the inner rotation curves of small mass galaxies. Besides helping in interpreting the cuspy profile of dark matter halos observed in N-body simulations, this potential regulates the quantity of baryons within halos of different masses.

Runaway dilaton and equivalence principle violations.

In a recently proposed scenario, where the dilaton decouples while cosmologically attracted towards infinite bare string coupling, its residual interactions can be related to the amplitude of density fluctuations generated during inflation, and are large enough to be detectable through a modest improvement on present tests of free-fall universality. Provided it has significant couplings to either dark matter or dark energy, a runaway dilaton can also induce time variations of the natural "constants" within the reach of near-future experiments.